Kymera director exercises options for 1,000 shares

Kymera Therapeutics director Pamela Esposito exercised stock options to acquire 1,000 shares of Common Stock at an exercise price of $31.20 per share.

Accepted by SEC EDGAR 05/19/2026 - 04:05 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics director Pamela Esposito exercised stock options to acquire 1,000 shares of Common Stock at an exercise price of $31.20 per share. After the transaction, she held 1,000 Common shares directly and 9,000 stock options with a $31.20 exercise price expiring on June 18, 2034. The filing notes that the shares underlying this option grant are fully vested and exercisable.

Insider Trade Summary

1,000 shares exercised/converted

Exercise 2 txns

Insider Esposito Pamela

Role Director

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	1,000	$0.00	$0.00
Exercise	Common Stock	1,000	$31.20	$31K

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 contracts (Direct); Common Stock — 1,000 shares (Direct)

Holdings Before and After: Stock Option (Right to Buy), 10,000 to 9,000 contracts (Direct); Common Stock, 0 to 1,000 shares (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option are fully vested and exercisable.

Key Figures

Options exercised: 1,000 shares Exercise price: $31.20/share Shares held after: 1,000 shares +2 more

5 metrics

Options exercised 1,000 shares Common Stock acquired via option exercise on May 19, 2026

Exercise price $31.20/share Stock Option (Right to Buy) for Kymera Common Stock

Shares held after 1,000 shares Total Common Stock directly owned following the transaction

Options remaining 9,000 options Stock options outstanding after exercise, strike $31.20

Option expiration June 18, 2034 Expiration date of remaining Kymera stock options

Key Terms

Stock Option (Right to Buy), Exercise or conversion of derivative security, fully vested and exercisable, Common Stock

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

fully vested and exercisable financial

"The shares underlying this stock option are fully vested and exercisable."

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Pamela Esposito?

Kymera Therapeutics reported that director Pamela Esposito exercised stock options to acquire 1,000 Common shares. The options had a $31.20 exercise price per share, converting derivative rights into directly held stock without any reported same-day sale of the acquired shares.

At what price did Pamela Esposito exercise her Kymera Therapeutics (KYMR) stock options?

Pamela Esposito exercised Kymera stock options at an exercise price of $31.20 per share. This transaction covered 1,000 underlying Common shares, moving them from option form into directly held equity as reflected in the Form 4 filing for May 19, 2026.

How many Kymera Therapeutics (KYMR) shares does Pamela Esposito hold after this Form 4 transaction?

After the transaction, Pamela Esposito held 1,000 shares of Kymera Common Stock directly. In addition, she retained 9,000 stock options with a $31.20 exercise price, providing further potential future equity exposure if those options are exercised before their June 18, 2034 expiration.

What happens to Pamela Esposito’s Kymera Therapeutics (KYMR) stock options after this exercise?

Following the exercise of 1,000 options, 9,000 Kymera stock options remain outstanding for Pamela Esposito. These options, each with a $31.20 exercise price and a June 18, 2034 expiration, continue to give her the right to purchase additional Common shares in the future.

Are Pamela Esposito’s Kymera Therapeutics (KYMR) options fully vested and exercisable?

The filing states that the shares underlying this Kymera stock option grant are fully vested and exercisable. This means Esposito is entitled to exercise the remaining 9,000 options at any time before their June 18, 2034 expiration, subject to any applicable trading or company policies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Esposito Pamela

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		1,000	A	$31.2	1,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$31.2	05/19/2026		M			1,000	(1)	06/18/2034	Common Stock	1,000	$0	9,000	D

Explanation of Responses:

1. The shares underlying this stock option are fully vested and exercisable.

	/s/ Bruce Jacobs, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)